GlassScriptPhysician profile
Suzanne J Sirota-Rozenberg
NPI 1841245859
$122,113.76
in general payments reported to CMS, 2019-2025
40 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $17K · 2021: $9,279 · 2022: $14K · 2023: $34K · 2024: $20K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Food and Beverage: $10K · Education: $319 · Travel and Lodging: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,360.00 |
| Food and Beverage | $10,250.05 |
| Education | $318.69 |
| Travel and Lodging | $172.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $100,032.21 | 2019-2025 | Aklief, Nemluvio, Dysport |
| Genzyme Corporation | $7,254.11 | 2019-2025 | |
| Abbvie INC. | $1,592.93 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Lilly USA, LLC | $1,327.00 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $980.12 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $908.31 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $874.23 | 2019-2024 | Otezla |
| Allergan, INC. | $807.04 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $736.28 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Pfizer INC. | $716.85 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $702.37 | 2019-2024 | Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $597.31 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $588.74 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $570.26 | 2020-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.89 | 2022-2024 | Spevigo, Cyltezo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Sirota-Rozenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.